COMMUNIQUÉS West-GlobeNewswire

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
02/02/2026
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million upfront payment [...]
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
02/02/2026
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute [...]
Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of ≈ $150 Million and Provides Q1 2026 Outlook
02/02/2026
VANCOUVER, British Columbia, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) (“Hydreight” or the “Company”), a provider of compliant digital health infrastructure and [...]
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
02/02/2026
Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis Preliminary case reports suggesting clinical benefit underscore unmet need for development of [...]
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
02/02/2026
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
02/02/2026
WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address [...]
Iridex Announces Plans to Relocate Headquarters
02/02/2026
Move expected to generate significant cost savings MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical [...]
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
02/02/2026
Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding [...]
Nova Leap Health Corp. Launches Palliative Care Division In Nova Scotia Through Earth Angels Home Care
02/02/2026
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Feb. 02, 2026 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
02/02/2026
Deficiencies limited to packaging and administration Company believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026 Remains well-capitalized and anticipates ending 2026 with significant [...]
Guidelight Expands to California with Opening of Los Angeles Clinic
02/02/2026
Leading Provider of Evidence-Based Mental Health Treatment Brings Services to West LA LOS ANGELES, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Guidelight, a leader in evidence-based mental health care, is proud to announce the [...]
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
02/02/2026
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly [...]
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
02/02/2026
SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
02/02/2026
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, [...]
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
02/02/2026
22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab doses Weight [...]
Landmark Living Brain Study Published in CELL Identifies a Novel Molecular Roadmap Governing Human Brain Aging
02/02/2026
Mount Sinai and BPGbio scientists uncover novel molecular drivers from live brain samples that direct human brain structure and function from early development through aging: Creates a completely new molecular [...]
Groundbreaking therapy for advanced heart failure
02/02/2026
Repairon expands to North America to Accelerate Clinical Trials and Product Development GÖTTINGEN, Germany, Feb. 02, 2026 (GLOBE NEWSWIRE) -- German biotech company Repairon GmbH announced the formation of its fully [...]
Thérapie révolutionnaire pour l’insuffisance cardiaque avancée
02/02/2026
Repairon étend ses activités à l’Amérique du Nord pour accélérer son programme clinique et le développement de ses produits GÖTTINGEN, Allemagne, 02 févr. 2026 (GLOBE NEWSWIRE) -- La société de biotechnologie allemande [...]
Agomab Announces Launch of Initial Public Offering
02/02/2026
ANTWERP, Belgium, February 2, 2026 (GLOBE NEWSWIRE) – AgomAb Therapeutics NV (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory [...]

Pages